Press release content from Business Wire. The AP news staff was not involved in its creation.
Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority
December 18, 2020 GMT
SAN FRANCISCO & NESS ZIONA, Israel--(BUSINESS WIRE)--Dec 18, 2020--
Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech innovation hub in Israel and is Atomwise’s second partnership with a global incubator hub.